Is ACADIA PHARMACEUTICALS INC (ACAD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.4% / 30% | 21.7% / 30% | 3.9% / 30% | 2.96% / 5% | ✓ HALAL |
| DJIM | 1.4% / 33% | 21.7% / 33% | 3.9% / 33% | 2.96% / 5% | ✓ HALAL |
| MSCI | 3.3% / 33% | 52.4% / 33% | 9.5% / 33% | 2.96% / 5% | ✗ NOT HALAL |
| S&P | 1.4% / 33% | 21.7% / 33% | 3.9% / 33% | 2.96% / 5% | ✓ HALAL |
| FTSE | 3.3% / 33% | 52.4% / 33% | 9.5% / 50% | 2.96% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 61.0% | |
| Operating Margin | 6.1% | |
| Net Margin | 36.5% | |
| Return on Equity (ROE) | 39.9% | |
| Return on Assets (ROA) | 4.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $110M |
| Free Cash Flow | $105M |
| Total Debt | $52M |
| Debt-to-Equity | 4.3 |
| Current Ratio | 3.8 |
| Total Assets | $1.6B |
Price & Trading
| Last Close | $21.47 |
| 50-Day MA | $23.48 |
| 200-Day MA | $23.74 |
| Avg Volume | 1.6M |
| Beta | 0.8 |
|
52-Week Range
$13.40
| |
About ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Purification Calculator
As a halal stock with 2.96% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ACADIA PHARMACEUTICALS INC (ACAD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ACADIA PHARMACEUTICALS INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ACADIA PHARMACEUTICALS INC's debt ratio?
ACADIA PHARMACEUTICALS INC's debt ratio is 1.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.3%.
Does ACADIA PHARMACEUTICALS INC require dividend purification?
Yes, ACADIA PHARMACEUTICALS INC has an impermissible income ratio of 2.96%, which means 2.96% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are ACADIA PHARMACEUTICALS INC's key financial metrics?
ACADIA PHARMACEUTICALS INC has a market capitalization of $3.5B, trailing P/E ratio of 9.0, and revenue of $1.1B. The company maintains a gross margin of 61.0% and a net margin of 36.5%. Return on equity stands at 39.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.